Halotestin Overview, Dosing & Safety | Peptide Database

Halotestin (Fluoxymesterone)

Oral Anabolic Steroid | Extreme Strength & Aggression

Community Research

Join others researching Halotestin — share findings, ask questions, and learn from real experiences

Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use.

Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue. The compound's performance-enhancing effects are largely mediated through the central nervous system, increasing aggression, motivation, and perceived energy through androgen receptor activation in the brain. Fluoxymesterone also stimulates erythropoietin production, increasing red blood cell mass and oxygen-carrying capacity, which was the basis for its historical use in treating certain anemias. It enhances hemoglobin synthesis and may improve muscular endurance through improved oxygen delivery. The 17-alpha-methylation allows oral bioavailability but imposes significant hepatic stress, as the liver must process the intact steroid through first-pass metabolism. Fluoxymesterone suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, and its extreme androgenic load can rapidly affect mood, lipid profiles, and prostate tissue.

Molecular Data

Research Indications

Originally FDA-approved for testosterone replacement in hypogonadal men. Fluoxymesterone was used to treat delayed puberty and androgen deficiency, though it has been almost entirely replaced by injectable testosterone and transdermal preparations due to its hepatotoxicity and unfavorable side effect profile.

FDA-approved for palliative treatment of androgen-responsive, advanced inoperable breast cancer in women, typically 1-5 years post-menopause. This indication is rarely used today due to the availability of aromatase inhibitors and targeted therapies with superior safety profiles.

Used by powerlifters and strength athletes in the final 2-4 weeks before a competition to maximize strength output, aggression, and neural drive without adding bodyweight or water retention. The compound's effects on the central nervous system produce a pronounced increase in competitive intensity.

Employed by competitive bodybuilders in the last 2-4 weeks before stage to enhance muscle hardness, vascularity, and visual density without water retention. The non-aromatizing nature ensures no subcutaneous water accumulation during the critical final phase of contest preparation.

Historically used by fighters and combat sport athletes to increase aggression and power output while staying within a weight class, as it adds no water weight. This use carries significant ethical and regulatory concerns given anti-doping testing.

Dosing Protocols

Fluoxymesterone is exclusively administered orally as a 17-alpha-alkylated steroid. Pharmaceutical tablets have been produced in 2 mg, 5 mg, and 10 mg doses. The 17-alpha-methylation provides oral bioavailability but makes halotestin one of the most hepatotoxic oral anabolic steroids available. Due to its extreme liver toxicity, cycles must be kept very short and liver support supplementation is considered essential.

Medical - Hypogonadism (Historical)

5-20 mg/day

Divided into 2-4 doses daily

Oral

Performance - Strength Peaking

10-20 mg/day

Split into 2 doses (morning and 1-2 hours pre-training)

Performance - Pre-Contest Hardening

Split into 2 doses daily

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)

Pronounced aggression and irritability

HDL cholesterol suppression and LDL elevation

Elevated blood pressure

Headaches (frequently reported, may be related to blood pressure changes)

Suppression of endogenous testosterone production

Oily skin and acne

Decreased appetite (potentially related to liver stress)

Stop Signs - Discontinue if:

Yellowing of skin or eyes (jaundice, indicating serious liver damage)

Severe or persistent right upper quadrant abdominal pain

Dark-colored urine or pale/clay-colored stools

Extreme or uncontrollable aggression that affects daily functioning or relationships

Persistent severe headaches unresponsive to standard treatment

Chest pain, difficulty breathing, or signs of cardiovascular distress

Unusual bleeding or bruising

Nausea, vomiting, or profound fatigue suggesting hepatic compromise

Contraindications

Known or suspected prostate cancer

Breast cancer in males

Pregnancy (Category X - causes fetal harm)

Active liver disease or existing hepatic impairment

Severe cardiovascular disease or uncontrolled hypertension

Hypercalcemia

Nephrosis or nephrotic phase of nephritis

History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use

Hypersensitivity to fluoxymesterone or any formulation component

Quality Checklist

Good Signs

Pharmaceutical-grade product with manufacturer lot number and expiration date (Halotestin brand or authorized generic)

Proper labeling with correct dosage per tablet, lot number, and expiration date

Tablets are uniform in size, color, and shape with consistent imprinting

Prescribed by a licensed physician with documented clinical indication

Third-party lab testing confirming identity, potency, and absence of contaminants

Warning Signs

Underground lab (UGL) product without pharmaceutical-grade verification

Tablets with inconsistent sizing, crumbling, or no manufacturer imprint

No third-party certificate of analysis available

Product labeled at unusually high doses per tablet (above 20 mg)

Packaging that appears unprofessional or has spelling errors

Bad Signs

Product with no labeling or verifiable source information

Lab testing reveals substituted compound (methyltestosterone or other cheaper steroid sold as halotestin)

Contaminated product with heavy metals, bacteria, or undisclosed active ingredients

Expired product or product stored improperly

Severe or unexpected side effects suggesting mislabeled or adulterated product

Frequently Asked Questions

Why is halotestin only used for 2-4 weeks, and what happens if I run it longer?

Halotestin is one of the most hepatotoxic oral steroids available due to its 17-alpha-methylation, causing severe liver enzyme elevation (ALT/AST increases 5-10x) even at moderate doses. Running it beyond 4 weeks substantially increases risk of cholestatic jaundice, peliosis hepatis, and potentially permanent liver damage. The risk-benefit calculation only justifies 2-4 weeks of use for pre-competition strength peaking or hardening; longer durations expose you to cumulative hepatic injury without additional performance benefit. Always include liver support (TUDCA 500mg + NAC 1200mg daily) and monitor liver enzymes weekly during use.

Is halotestin muscle-building, or is it purely for strength and aggression?

Halotestin is primarily a strength and neural drive enhancer rather than a muscle-builder. Despite its 1900 androgenic rating, its actual anabolic effect on skeletal muscle tissue is surprisingly modest compared to testosterone or trenbolone. The strength gains are largely mediated through increased aggression, motivation, and red blood cell production (enhanced oxygen delivery), which improve training intensity rather than building new muscle directly. Use halotestin in the final 2-4 weeks of a cycle to peak strength and hardness for competition, not as a primary muscle-building agent. The real muscle gains should come from the base testosterone or other injectables earlier in the cycle.

Can I combine halotestin with other oral steroids?

No—combining halotestin with other 17-alpha-alkylated orals (Anavar, Dbol, Winstrol, Tbol) is one of the most dangerous combinations in performance-enhancing drug use. Both compounds stress the liver independently; stacking them multiplies hepatotoxic risk exponentially, potentially causing acute liver failure. Never combine multiple oral steroids. If you need additional effects during halotestin's 2-4 week window, use injectable testosterone as your base only; save other oral compounds for separate phases of the cycle or defer them to after halotestin concludes.

How quickly does halotestin kick in, and what's the timeline for strength gains?

Halotestin has a rapid onset due to its 9.5-hour half-life and the fact that it achieves peak levels quickly with twice-daily oral dosing. Most users notice increased aggression and focus within 1-3 days, with tangible strength gains becoming obvious by day 4-10. Peak strength and performance effects occur at week 2-3, making it ideal for peaking in the final 2-3 weeks before a competition or powerlifting meet. This rapid onset and short window is why halotestin is exclusively used as a short-term peaking tool—effects fade quickly after stopping, and liver toxicity accumulates with extended use.

References

Comprehensive pharmacological profile of fluoxymesterone detailing its extreme androgenic potency (1900 androgenic rating), non-aromatizing nature, and clinical applications in hypogonadism and breast cancer, alongside documentation of its significant hepatotoxicity relative to other oral anabolic steroids.

Review documenting the spectrum of hepatotoxicity associated with 17-alpha-alkylated anabolic steroids including fluoxymesterone, ranging from transient enzyme elevations to cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma, with fluoxymesterone identified as one of the most hepatotoxic compounds in this class.

Landmark paper establishing the role of androgens including fluoxymesterone in stimulating erythropoietin production and red blood cell synthesis, which formed the basis for the historical use of halotestin in treating aplastic anemia and other refractory anemias before the availability of recombinant erythropoietin.

Early clinical study comparing fluoxymesterone to testosterone propionate in breast cancer patients, demonstrating that oral fluoxymesterone achieved comparable nitrogen retention and anti-tumor activity to injectable testosterone, establishing its clinical viability as an oral androgen therapy.

Comprehensive review of adverse effects associated with anabolic-androgenic steroid use including cardiovascular, hepatic, endocrine, and psychological effects, with specific discussion of the elevated hepatotoxic risk associated with 17-alpha-alkylated compounds such as fluoxymesterone.

Related Peptides

A testosterone base is considered essential when using halotestin. Fluoxymesterone will rapidly suppress endogenous testosterone production, and it provides no estrogenic activity. Without exogenous testosterone, users will experience symptoms of low estrogen (joint pain, low libido, poor mood) and hypogonadism. Typical combination: TRT-dose testosterone (100-200 mg/week) alongside halotestin 10-20 mg/day for the final 2-4 weeks of a cycle.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.